Apotex Pharmachem India Pvt Ltd. – FDA Warning Letter, Jan 31, 2014

The FDA issued a Warning Letter to Apotex Pharmachem India Pvt. Ltd. following a January 27-31, 2014 inspection, identifying significant deviations from current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (APIs). These deviations render their APIs adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The firm's responses were deemed insufficient. Key violations include the failure to maintain complete and accurate raw laboratory data, with evidence of retesting until acceptable results were obtained and OOS results being discarded or not reported/investigated, raising serious data integrity concerns. The firm also failed to adequately investigate and document out-of-specification results, include adequate documentation during complaint investigations, and record activities contemporaneously. These issues, particularly data integrity and OOS investigations, were repeat observations from previous 2006 and 2010 inspections. The FDA expressed serious concerns about data reliability, laboratory credibility, and management oversight. The letter mandates a comprehensive data integrity audit, risk assessment, robust corrective and preventive action plan, and a strong quality system with direct corporate oversight, referencing ICH Q7 guidance. The firm must provide a list of all affected API batches and respond within fifteen working days. Failure to correct these deviations could lead to the withholding of new drug applications and refusal of admission of products into the U.S.